Ratings Idorsia Ltd

Equities

IDIA

CH0363463438

Market Closed - Swiss Exchange Other stock markets 11:31:51 2024-04-24 am EDT			5-day change	1st Jan Change
1.906 ^CHF	-4.70%		-11.35%	-9.84%

Apr. 11	Swiss Market Index Falls as ECB Signals June Rate Cut	MT
Apr. 11	Idorsia to Revise July 2024 Convertible Bond Terms, Conditions	MT

Summary

According to Refinitiv, the company's ESG score for its industry is good.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
IDORSIA LTD	-10.74%	393M	A-
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B	B+
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B	B+
ARGENX SE	+3.29%	22.19B	B
BIONTECH SE	-16.16%	21.33B	B+
GENMAB A/S	-7.31%	18.68B	A-
WUXI APPTEC CO., LTD.	-41.41%	16.6B	A-
BEIGENE, LTD.	-22.87%	14.52B	B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B	C+
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes